John L. Marshall, MD: Zolbetuximab is a drug that you probably don’t know the name of, but you’re going to soon. Though you may have heard of claudin 18.2. Now, that’s been in the literature for a ...
Comparing outcomes for early and late drainage of malignant ascites. Background: Black individuals, including African Americans, experience a disproportionate cancer burden and exhibit the lowest ...
The Administrative Core will provide for overall direction, coordination, and administration of the Case Gl SPORE, including oversight of the SPORE Executive Committee, SPORE Internal Advisory Board, ...
A population-based study drew a possible connection between gastrointestinal (GI) symptoms and the multiple sclerosis (MS) prodrome. Patients with multiple sclerosis (MS) endure higher rates of drug ...
71.4% of MetaXplore™ reports from 4,616 patients identified actionable results 41.9% tested positive for abnormal microbiome markers linked to gastrointestinal health 9.9% tested positive for ...
BOSTON--(BUSINESS WIRE)--GI Dynamics, a medical device company that is developing the EndoBarrier® System for patients diagnosed with type 2 diabetes and obesity, announced results from a multicenter ...
Gastrointestinal disorders may affect around 40% of people worldwide, according to one recent study. GI disorders can include several conditions, including celiac disease, gastritis, Crohn's disease, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results